Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Tiffany

Anesthesiology Tucson, AZ Medical Doctor

NPI 1407964737 CMS profile 245738

4601 E Broadway Blvd, Tucson, AZ 85711

Open in the dashboard

General payments

$6,568

186 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Tiffany of Tucson, AZ is reported in the CMS Open Payments database as having received $6,568 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $98 3
2024 General $325 3
2023 General $2,549 29
2022 General $1,027 39
2021 General $1,105 47
2020 General $315 13
2019 General $1,149 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Tiffany
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Mark Tiffany were reported at $98. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Mark Tiffany Anesthesiology median Middle half National median
2019 $1,149 $72 $23–$151 $163
2020 $315 $36 $17–$120 $114
2021 $1,105 $49 $21–$135 $132
2022 $1,027 $52 $22–$144 $149
2023 $2,549 $53 $23–$143 $160
2024 $325 $55 $25–$150 $164
2025 $98 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,552 46 payments
  2. Medtronic, Inc. $1,158 7 payments
  3. Forte Bio-Pharma LLC $448 4 payments
  4. Abbott Laboratories $357 18 payments
  5. Collegium Pharmaceutical, Inc. $353 27 payments
  6. Scilex Pharmaceuticals Inc. $261 19 payments
  7. GRT US Holding, Inc. $193 5 payments
  8. Nevro Corp. $182 2 payments
  9. SPR Therapeutics, Inc $137 1 payment
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $112 8 payments
  11. Other $815 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,203 180 payments
  2. Travel and Lodging $1,366 6 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $918 5 payments
  2. WaveWriter Alpha Prime 16 $840 17 payments
  3. XTAMPZA $329 26 payments
  4. GENERAL PAIN MANAGEMENT $327 7 payments
  5. KYPHON EXPRESS II KYPHOPAK TRAY $240 2 payments
  6. NALOCET Pain $237 2 payments
  7. NALOCET Pain $211 2 payments
  8. PROLATE Pain $211 2 payments
  9. Qutenza $193 5 payments
  10. PROLATE Pain $191 1 payment
  11. Other $3,060 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

933

Median for Pain Management: 951

Drug cost

$47,529

Median for Pain Management: $26,034

Branded share of claims

29%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 64 $14,371
Belbuca Buprenorphine Hcl Brand 17 $11,312
Xtampza Er Oxycodone Myristate Brand 14 $5,630
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 102 $2,943
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 86 $2,638
Oxycodone Hcl Generic 91 $1,713
Morphine Sulfate Er Morphine Sulfate Brand 52 $1,281
Naloxone Hcl Generic 20 $1,227
Gabapentin Generic 79 $1,213
Pregabalin Generic 44 $1,021

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$56,835

Of which drugs: $625

Medicare patients

158

Average age 75

Services billed

850

91 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 30%
Ischemic heart disease 28%
Osteoporosis 28%
Chronic kidney disease 22%
Depression 20%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record